Business Wire - August 14, 2006
The license agreements require that the generic manufacturers meet certain national and international regulatory standards and include a technology transfer to enable expeditious production of large volumes of high-quality generic versions of tenofovir. In addition, these agreements allow the manufacture of commercial quantities of both active pharmaceutical ingredient (API) and finished product. Gilead continues to pursue license agreements with additional Indian generic manufacturers and is currently in ongoing discussions with a number of Indian companies.
"We are pleased to have finalized agreements with Emcure, Hetero, and Strides Arcolab and anticipate granting additional licenses over time to help meet the needs of patients in the developing world," said John C. Martin, PhD, President and CEO of Gilead Sciences. "We hope that competition among multiple manufacturers will result in even lower prices for Viread in the developing world than what Gilead is currently offering. Gilead is committed to and making every effort to increase access worldwide, particularly in resource-limited areas, where the epidemic has hit the hardest."
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia. For more information on Gilead Sciences, please visit the company's website at www.gilead.com.
Viread is a registered trademark of Gilead Sciences, Inc.
CONTACT: Gilead Sciences, Inc.
Susan Hubbard, 650-522-5715 (Investors)
Jenna Conley, 650-522-5078 (Media)
SOURCE: Gilead Sciences, Inc.
060814
BW060820
Copyright © 2006 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .